Kinetics of the inflammatory response during experimental Babesia rossi infection of beagle dogs.

Babesia rossi causes severe morbidity and mortality in dogs in sub-Saharan Africa, and the complications associated with this disease are likely caused by an unfocused, excessive inflammatory response. During this experimental B. rossi study we investigated inflammatory marker and cytokine kinetics during infection and after treatment. We aimed to determine whether infectious dose and treatment would influence the progression of the inflammatory response and clinical disease. Six healthy male beagle dogs formed the study population, one was used to raise the infectious inoculum, three were administered a high B. rossi infectious dose (HD group) and two a low infectious dose (LD group). Clinical examination, complete blood count (CBC) and C-reactive protein (CRP) were determined daily. Cytokines were quantified on stored plasma collected during the study, using a canine specific cytokine magnetic bead panel (Milliplex©). The experiment was terminated and treatment administered when predetermined experimental or humane endpoints were reached. Parasitemia occurred on day 1 and 3 in the HD and LD groups respectively. The rate of increase in parasitemia in the HD group was significantly faster than that seen in the LD group. Significant differences were found in heart rate, blood pressure, interferon gamma (INFγ), keratinocyte chemoattractant (KC), INFγ-induced protein 10 (IP10), granulocyte-macrophage colony-stimulating factor (GM-CSF), monocyte chemoattractant protein 1 (MCP1), tumor necrosis factor alpha (TNFα), interleukin 2 (IL-2), IL-6, IL-7, IL-8, IL-10 IL-15, IL-18, CRP, neutrophils and monocytes between groups at multiple time points during the course of the infection. Our findings suggest that the initiation of inflammation occurs before the onset of clinical disease in B. rossi infection and infectious dose influences the onset of the inflammatory response. Treatment enhances the inflammatory response in the immediate post-treatment period which may contribute to disease associated complications. Finally, we found that there is an imbalance in pro/anti-inflammatory cytokine concentrations during infection which may promote parasite replication.

Vascular endothelial growth factor concentrations in dogs with spirocercosis.

BACKGROUND: Vascular endothelial growth factor (VEGF) is a potent proangiogenic factor associated with tumor development. Spirocerca lupi is a nematode of canids that induces an esophageal nodule that progresses to a sarcoma in 25% of cases. Determination of neoplastic transformation is challenging and usually based on endoscopy-guided biopsies under general anesthesia, an expensive procedure that often yields nondiagnostic, necrotic samples. HYPOTHESIS: Circulatory VEGF concentrations are increased in dogs with neoplastic spirocercosis and can distinguish between dogs with neoplastic and nonneoplastic disease. ANIMALS: A total of 24 client-owned dogs, 9 nonneoplastic, 9 neoplastic, and 6 controls. METHODS: Case-control study. Plasma and serum VEGF concentrations at the time of diagnosis were compared with those of healthy controls. Measurement of VEGF was performed using a canine-specific ELISA. Kruskal-Wallis and Dunn's tests were used for statistical analysis with significance set at P < .05. RESULTS: The median plasma VEGF concentrations of dogs with neoplastic spirocercosis were 629 pg/mL (range, 282-2,366) higher than both the nonneoplastic (<39.5 pg/mL; range, <39.5-716) and control dogs (<39.5 pg/mL; all values, <39.5; P = .0003). The median serum VEGF concentration of the neoplastic dogs was 69 pg/mL (range, <39.5-212) higher than the nonneoplastic (<39.5 pg/mL; range, <39.5-44.13) and control dogs (<39.5 pg/mL; all values, <39.5; P = .001). CONCLUSIONS AND CLINICAL IMPORTANCE: Both plasma and serum VEGF concentrations can be used to differentiate nonneoplastic and neoplastic spirocercosis. The role of VEGF in neoplastic transformation of S. lupi-induced nodules and the potential utility of anti-VEGF drugs in spirocercosis-induced sarcoma warrant further investigation.

Serum C-reactive protein concentration in benign and malignant canine spirocercosis.

BACKGROUND: Spirocerca lupi is a nematode of canids that forms a nodule in the esophagus that can undergo neoplastic transformation. C-reactive protein (CRP) is a major acute phase protein in the dog that has been used for treatment, monitoring, and prognostication in inflammatory and neoplastic disease. HYPOTHESIS/OBJECTIVES: The objectives of this study were to determine if serum CRP concentration (1) is increased in canine spirocercosis, (2) can be used to determine neoplastic transformation, and (3) can be used to monitor response to treatment in benign spirocercosis. ANIMALS: Forty-two dogs naturally infected with S. lupi and 21 control dogs. METHODS: A retrospective study was performed. The infected cases were divided into benign (n = 28) or malignant (n = 14) spirocercosis. CRP was performed on all of the spirocercosis and control cases at presentation. Statistical analysis was done by the one-way analysis of variance and Student's t-test. RESULTS: The mean CRP concentration in the benign cases was 60.4 ± 48.0 mg/L and that of the malignant cases was 76.5 ± 44.8 mg/L; both values were significantly higher (P < .001) than those of the control group where the mean was 13.4 ± 17.9 mg/L. The mean CRP concentration for the convalescent sera in the benign group was lower than the pretreatment concentrations (P= .01). CONCLUSION AND CLINICAL IMPORTANCE: CRP cannot be used to differentiate between benign and malignant spirocercosis. There is a decrease in CRP concentration in dogs with benign spirocercosis once treatment has commenced. Serial CRP measurement can be used to monitor response to treatment in benign spirocercosis.